Wiki
Linagliptin
Linagliptin (Tradjenta)
Clinical Summary
Linagliptin is a DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor), marketed as Tradjenta by Boehringer Ingelheim and Eli Lilly.
Long-term continuous medication confirmed. Documented on both November 2022 medication list ("Trajenta") and May 2026 handwritten prescription ("Tradjenta") at the same dose (5 mg once daily morning). Dose unchanged across at least 3.5 years.
Dosing History
| Date | Dose | Frequency | Route | Context |
|---|---|---|---|---|
| 2022-11-25 | 5 mg | Once daily (morning) | Oral | "Trajenta" brand — Nov 2022 medication list |
| 2026-05-04 | 5 mg | Once daily (morning, 1-0-0) | Oral | "Tradjenta" brand — handwritten Rx |
[!info] Long-Term Continuity: at least Nov 2022 → May 2026
Dose unchanged. Brand spelling variant (Trajenta → Tradjenta) — same medication.
Indication
Type 2 Diabetes Mellitus. Used as adjunct to diet and exercise to improve glycemic control.
Pharmacology
- Drug class: DPP-4 inhibitor (gliptin)
- Mechanism: Inhibits DPP-4 enzyme, which degrades incretin hormones (GLP-1, GIP). Result: increased insulin secretion (glucose-dependent), decreased glucagon secretion, improved postprandial glucose control.
- Half-life: ~12 hours (terminal half-life >100 hours)
- Standard dose: 5 mg once daily (no dose adjustment needed for renal/hepatic impairment)
Advantages in AML/CKD Setting
- No renal dose adjustment required — unique among DPP-4 inhibitors (excreted primarily via enterohepatic system, not kidneys)
- No hepatic dose adjustment required
- Low hypoglycemia risk (glucose-dependent insulin secretion)
- Weight-neutral
Monitoring
- Fructosamine (preferred glycemic marker in AML)
- Fasting and postprandial glucose
- Renal function (baseline, periodic)
- Pancreatitis symptoms (rare but serious)
Drug Interactions
- Minimal drug interactions
- No CYP450 metabolism (not affected by posaconazole)
- Can be used with insulin, metformin, SGLT2 inhibitors
Adverse Effects
- Generally well-tolerated
- Nasopharyngitis (most common)
- Pancreatitis (rare but serious — discontinue if suspected)
- Hypersensitivity reactions (rare): angioedema, urticaria, rash
- Arthralgia (rare)
Related
- Diabetes Mellitus — Primary indication
- Metformin — Likely co-administered (see "Glulucamio" on same Rx)
- Insulin Degludec — Co-administered basal insulin
- Fructosamine — Preferred glycemic marker in AML setting
Medication page created during ingest of 2026-05-04 handwritten prescription.